CY2246B1 - Pharmaceutical compositions comprising calcitonin - Google Patents

Pharmaceutical compositions comprising calcitonin

Info

Publication number
CY2246B1
CY2246B1 CY0100038A CY0100038A CY2246B1 CY 2246 B1 CY2246 B1 CY 2246B1 CY 0100038 A CY0100038 A CY 0100038A CY 0100038 A CY0100038 A CY 0100038A CY 2246 B1 CY2246 B1 CY 2246B1
Authority
CY
Cyprus
Prior art keywords
calcitonin
pharmaceutical compositions
calcium deficiency
deficiency diseases
treating calcium
Prior art date
Application number
CY0100038A
Other languages
English (en)
Inventor
Tudor Phillips Judith Arvinte
Amelia Cudd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2246B1 publication Critical patent/CY2246B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CY0100038A 1991-04-23 2001-11-19 Pharmaceutical compositions comprising calcitonin CY2246B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108634A GB9108634D0 (en) 1991-04-23 1991-04-23 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY2246B1 true CY2246B1 (en) 2003-07-04

Family

ID=10693744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0100038A CY2246B1 (en) 1991-04-23 2001-11-19 Pharmaceutical compositions comprising calcitonin

Country Status (19)

Country Link
US (1) US5593962A (de)
EP (1) EP0510913B1 (de)
JP (1) JP3532580B2 (de)
KR (1) KR100245534B1 (de)
AT (1) ATE194775T1 (de)
AU (1) AU653395B2 (de)
CA (1) CA2066532C (de)
CY (1) CY2246B1 (de)
DE (1) DE69231263T2 (de)
DK (1) DK0510913T3 (de)
ES (1) ES2150418T3 (de)
GB (1) GB9108634D0 (de)
GR (1) GR3034414T3 (de)
IE (1) IE921278A1 (de)
IL (1) IL101622A (de)
MX (1) MX9201825A (de)
NZ (1) NZ242440A (de)
PT (1) PT510913E (de)
ZA (1) ZA922899B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
EP1161257A2 (de) * 1999-03-17 2001-12-12 Novartis AG Tgf-beta enthaltende pharmazeutische zusammensetzungen
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
MXPA05003318A (es) * 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
AU2008354530B2 (en) * 2008-04-07 2014-02-27 Indian Institute Of Science Compositions useful for the treatment of diabetes and other chronic disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions

Also Published As

Publication number Publication date
CA2066532A1 (en) 1992-10-24
MX9201825A (es) 1992-10-01
NZ242440A (en) 1993-10-26
DE69231263D1 (de) 2000-08-24
IL101622A (en) 1996-06-18
IE921278A1 (en) 1992-11-04
CA2066532C (en) 2003-08-19
DE69231263T2 (de) 2000-12-21
GR3034414T3 (en) 2000-12-29
DK0510913T3 (da) 2000-10-16
JPH05139993A (ja) 1993-06-08
US5593962A (en) 1997-01-14
PT510913E (pt) 2000-12-29
AU653395B2 (en) 1994-09-29
KR100245534B1 (ko) 2000-03-02
IL101622A0 (en) 1992-12-30
AU1506692A (en) 1992-10-29
EP0510913A2 (de) 1992-10-28
GB9108634D0 (en) 1991-06-12
EP0510913B1 (de) 2000-07-19
ES2150418T3 (es) 2000-12-01
EP0510913A3 (en) 1993-12-15
ATE194775T1 (de) 2000-08-15
JP3532580B2 (ja) 2004-05-31
ZA922899B (en) 1993-10-22

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
MX9204229A (es) Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.
HK1010484A1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
GR3035682T3 (en) Non-glycosylated fgf-4 and compositions containing the same.
IL87421A (en) Pharmaceutical compositions containing 5-amino (or substituted amino) - 1,2,3-triazoles
SE9802937D0 (sv) Novel compounds
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ZA884418B (en) Pharmaceutical dosage unit
CY2246B1 (en) Pharmaceutical compositions comprising calcitonin
GB9516012D0 (en) Pharmaceutical composition
NZ222434A (en) Tissue factor protein lacking its naturally associated phospholipid
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
GB9516967D0 (en) Pharmaceutical composition
PL345204A1 (en) Compounds with growth hormone releasing properties
IL89392A0 (en) Compositions for the treatment of osteoporosis in humans comprising 24,25-dihydroxy-vitamin d3
IL96455A0 (en) Pharmaceutical compositions for the treatment of hsv
GB9217547D0 (en) Leather treatment compositions
EP0495226A3 (en) 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
EP0624368A3 (de) Verwendung einer Zusammensetzung zur Stimulation der Glutathion-Synthese für die Herstellung eines Medikaments zur Behandlung von AID.
PH31066A (en) Treatment composition.
ZA96446B (en) Use of 3,4-diphenyl chromans for the manufacture of pharmaceutical composition for the treatment or prophylaxis of obesity
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.